Tr1X

Sonoma Biotherapeutics

This biotechnology company develops engineered regulatory T cell therapies for patients with autoimmune and inflammatory diseases.

TRexBio

This biotechnology company develops immunoregulatory medicines for patients with autoimmune and inflammatory diseases by decoding regulatory T cell function in human tissues.

Dualyx

This company develops immune-modulating therapies targeting regulatory T cells to treat patients with autoimmune diseases.

ActiTrexx

This clinical-stage biotechnology company develops cellular therapies using activated regulatory T cells to prevent transplant rejection and autoimmune disorders in stem cell transplantation patients.

Regcell

This biotechnology company develops regulatory T-cell therapies using an epigenetic reprogramming platform to treat patients with autoimmune diseases and inflammatory conditions.

Quell Therapeutics

This clinical-stage company develops engineered T-regulatory cell therapies for patients with autoimmune diseases, inflammatory conditions and organ transplant rejection.

SEITO Biologics AG

This biotechnology company develops selective regulatory T cell engagers to treat patients suffering from autoimmune diseases, chronic inflammation and organ transplant rejection.

Egle Therapeutics

This biotechnology company develops precision medicines that modulate regulatory T cells to treat patients with autoimmune diseases and cancer.